Rapiclav 625 is a semi-synthetic Beta-lactam antibiotic. Its main components are Amoxicillin and Clavulanic Acid with a total content of 625 mg. Rapiclav 625 is widely indicated for treating infections of the respiratory tract, urinary tract, skin, and musculoskeletal system, among others. Understanding the basic information of Rapiclav 625 will bring the best treatment effectiveness for patients.
1. What are the uses of Rapiclav 625?
Rapiclav 625 is commonly presented as film-coated tablets and is also available as oral suspension and powder for suspension. Rapiclav 625 is indicated for the treatment of the following cases:
• Upper respiratory tract infections: Tonsillitis, otitis media, sinusitis.
• Lower respiratory tract infections: Bronchitis, acute or chronic pneumonia caused by Haemophilus influenzae and Moraxella catarrhalis.
• Urinary tract infections: Pyelonephritis, urethritis, cystitis caused by Escherichia coli, Klebsiella, and Enterobacter.
• Skin infections: Boils, wound infections, abscesses caused by Staphylococcus aureus, Escherichia coli, and Klebsiella.
• Dental abscesses.
• Bone and joint infections: Osteomyelitis.
• Pregnancy-related infections: Postpartum infections, infections due to miscarriage, infections due to abortion.
• Other infections: Postoperative infections, peritonitis, intra-abdominal infections.
• Septicemia.
Conversely, Rapiclav 625 is contraindicated in patients with:
• Hypersensitivity to any component of Rapiclav 625.
• History of allergy to drugs containing Amoxicillin or Clavulanic Acid.
• History of allergy to Beta-lactam antibiotics.
• Severe hepatic or renal failure.
• History of jaundice due to antibiotic use.
• Children weighing less than 40kg.
2. Dosage and administration of Rapiclav 625
Adults and children ≥ 40 kg:
• Usual dose: 1 tablet/time x 2 times/day.
• Severe infections: 1 tablet/time x 3 times/day.
Children < 40 kg:
• Oral suspension or powder for suspension is usually used: 20/5 mg/kg/day to 60/15 mg/kg/day x 3 times/day.
• Tablet use is not recommended.
Patients with renal failure: Dosage adjustment based on Creatinine Clearance (CrCl):
• CrCl 10-30 mL/min: 1 tablet/time x 2 times/day.
• CrCl < 10 mL/min: 1 tablet/time x 1 time/day.
• Hemodialysis: 1 tablet/time x 1 time/day. An additional dose should be administered during and at the end of each dialysis session.
3. Adverse effects of Rapiclav 625
Prolonged or high-dose administration of Rapiclav 625 may be associated with the following infrequent adverse effects:
• Gastrointestinal disorders: Diarrhea, nausea, vomiting, indigestion, liver disorders such as hepatitis, cholestatic jaundice, elevated liver enzymes, pseudomembranous colitis.
• Neurological disorders: Dizziness, headache, hyperactivity, convulsions, aseptic meningitis.
• Skin symptoms: Erythema, itching, Stevens-Johnson syndrome, epidermal necrolysis, exfoliative dermatitis, acute generalized exanthematous pustulosis
• Hematological disorders: Hemolytic anemia, leukopenia, eosinophilia, thrombocytopenia.
• Immune disorders: Anaphylaxis, angioedema.
If you experience these symptoms or other unwanted symptoms after using Rapiclav 625, immediately inform your treating physician or go to the nearest medical facility for timely treatment
4. Precautions for using Rapiclav 625
• Precautions when using Rapiclav 625 in the following cases: Patients with severe hepatic or renal failure need dose reduction and monitoring by liver and kidney function tests before, during, and after using the drug.
• In patients with renal impairment receiving Rapiclav 625, adequate hydration and maintenance of urine output are essential to minimize the risk of crystalluria.
• Pregnancy: Data regarding the teratogenic potential of Rapiclav 625 in pregnant women are limited. Furthermore, some reports in women with preterm delivery suggest that prophylactic administration of Rapiclav 625 in cases of premature rupture of membranes may increase the risk of necrotizing enterocolitis in neonates. Therefore, a careful risk-benefit assessment is warranted when considering Rapiclav 625 treatment during pregnancy.
• Breastfeeding women: Studies show that both Amoxicillin and Clavulanic Acid can pass into breast milk, thereby causing diarrhea or mucosal fungal infections in breastfed infants. Therefore, Rapiclav 625 should only be used when necessary.
• People who drive or operate machinery should be careful when using Rapiclav 625 because they may experience side effects such as headaches, dizziness, and seizures.
5. Drug interactions with Rapiclav 625
• Concurrent use of Rapiclav 625 with anticoagulants should be avoided due to the potential for prolonged prothrombin time and increased risk of bleeding.
• The renal excretion of Rapiclav 625 is reduced when co-administered with Probenecid.
• Rapiclav 625 may decrease the efficacy of oral contraceptives.
• Rapiclav 625 may reduce the excretion of Methotrexate, potentially leading to increased toxicity.
• Rapiclav 625 may cause false-positive results in urine glucose assays.
The above is general information about the ingredients, uses, dosage, and precautions when using Rapiclav 625. Carefully reading the instructions on the Rapiclav 625 product packaging and following the doctor's instructions will improve treatment effectiveness.
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
